PTGS2 and cancer: The current limited testing of aspirin (http://clinicaltrials.gov) as a therapeutic agent either in the adjuvant setting (ASCOLT and Big A trial) or in combination with other anti-cancer agents is in marked contrast to the number of studies that were initiated using selective Cox-2 inhibitors before 2004.